<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03786926</url>
  </required_header>
  <id_info>
    <org_study_id>2018-689-US001</org_study_id>
    <nct_id>NCT03786926</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, dose escalation and expansion clinical trial to evaluate the safety,
      tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, multicenter study of HMPL-689 administered orally to patients
      with relapsed or refractory lymphoma.

      This study will consist of a dose escalation stage (Stage 1) and a dose expansion stage
      (Stage 2).

      Dose Escalation Stage (Stage 1):

      This stage will end when any of the following criteria is met:

        -  The dose level 1 demonstrates an excessive toxicity, ie, 3 dose limiting toxicities
           (DLTs) are observed out of the first 3 patients at dose level 1.

        -  The maximum sample size is reached.

        -  The MTD and/or RP2D is confirmed.

      Dose Expansion Stage (Stage 2):

      To further characterize the safety and explore the preliminary anti-tumor activity of
      HMPL-689 at RP2D, patients with B cell lymphoma will be enrolled in the dose expansion stage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events as evaluated by the NCI CTCAE v5.0 grade</measure>
    <time_frame>From first dose to within 30 days after last dose</time_frame>
    <description>The safety and tolerability of HMPL-689 dose will be evaluated based on adverse events data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration (Cmax)</measure>
    <time_frame>from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to Cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)</time_frame>
    <description>To characterize the pharmacokinetic (PK) properties of HMPL-689 in patients with relapsed or refractory lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in a selected time interval (AUC0-t)</measure>
    <time_frame>from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to Cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)</time_frame>
    <description>To characterize the pharmacokinetic (PK) properties of HMPL-689 in patients with relapsed or refractory lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) defined as the proportion of patients who have a CR or PR</measure>
    <time_frame>from first dose to within 30 days of last dose</time_frame>
    <description>To evaluate the anti-tumor activity of HMPL-689 in patients with relapsed or refractory lymphoma according to: (1) Chronic Lymphocytic Leukemia (CLL) - modified International Workshop on CLL guidelines, (2) Waldenstrom's Macroglobulinemia (WM) - consensus of international workshops on WM, (3) Lymphomas other than CLL or WM: Lugano Response Criteria for Hodgkin and Non-Hodgkin's Lymphoma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients take HMPL-689 taken daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-689</intervention_name>
    <description>HMPL-689 is a PI3Kδ inhibitor</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. (ECOG) performance status of 0 or 1;

          2. Histologically confirmed lymphoma (tumor types are restricted to CLL, SLL, FL, MZL,
             LPL/WM, and MCL.)

          3. Patients with relapsed or refractory NHL for whom:.

               -  Standard of care treatment options no longer exist (Stage 1 only)

               -  Standard of care treatment options no longer exist with the exception of
                  PI3K-delta inhibitors (Stage 2 only)

          4. Expected survival of more than 24 weeks

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from study entry:

          1. Primary central nervous system (CNS) lymphoma;

          2. Any of the following laboratory abnormalities Absolute neutrophil count &lt;1.5×10^9/L,
             Hemoglobin &lt;90 g/L Platelets &lt;100 ×10^9/L

          3. Inadequate organ function, defined by the following:

               -  Total bilirubin &gt;1.5 times the upper limit of normal (× ULN)

               -  AST or ALT &gt; 2.5 × ULN

               -  Estimated creatinine clearance (CrCl) per Cockcroft-Gault

                    -  Dose Escalation stage of trial (Stage 1) - CrCl &lt; 50 mL/min

                    -  Dose Expansion stage of trial (Stage 2) - CrCl &lt;30 mL/min

          4. Clinically significant history of liver disease,

          5. Prior treatment with any PI3Kδ inhibitors

          6. Any prior use of the following: anti-neoplastic therapy within 3 weeks of study
             treatment, GCSF within 7 days of screening, steroid therapy or targeted
             anti-neoplastic intent within 7 days of treatment, monoclonal antibody within 3 weeks
             of treatment, any use of anti-cancer vaccine, prior administration of
             radioimmunotherapy within 3 months of study treatment, any use of strong CYP3A4
             induces within 7 days of study treatment, prior autologous transplant within 6 months
             of study treatment, prior allogenic stem cell transplant within 6 months of study
             treatment,

          7. Clinically significant active infection

          8. Major surgical procedure within 4 weeks prior to initiation of study treatment;

          9. Adverse events from prior anti-neoplastic therapy that have not resolved to Grade less
             than or equal to 1, except for alopecia;

         10. New York Heart Association (NYHA) Class II or greater congestive heart failure

         11. Congenital long QT syndrome or QTc &gt;470 msec;

         12. Currently use medication known to cause QT prolongation or torsades de pointes

         13. History of myocardial infarction or unstable angina within 6 months prior to
             initiation of study treatment;

         14. History of stroke or transient ischemic attack within 6 months prior to initiation of
             study treatment;

         15. Inability to take oral medication, prior surgical procedures affecting absorption, or
             active peptic ulcer disease;

         16. History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis);

         17. History of drug-induced pneumonitis;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tunde Lawrence, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison Medipharma Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nilanjan Ghosh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Levine Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan B Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory Winship Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tunde Lawrence, MD, PhD</last_name>
    <phone>9737862789</phone>
    <email>tundel@hmplglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alisha Khullar, MS</last_name>
    <phone>9732873081</phone>
    <email>alishak@hmplglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Travis</last_name>
      <phone>479-936-9900</phone>
    </contact>
    <investigator>
      <last_name>Patrick Travis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lepthien</last_name>
      <phone>714-698-0300</phone>
      <email>barbaraL@compcareresearch.com</email>
    </contact>
    <investigator>
      <last_name>Haresh Jhangiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Cohen, MD</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute- Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilanjan Ghosh, MD</last_name>
      <phone>980-442-4363</phone>
    </contact>
    <investigator>
      <last_name>Nilanjan Ghosh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Micah Burch</last_name>
      <phone>214-820-2687</phone>
    </contact>
    <investigator>
      <last_name>Micah Burch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mays Cancer Center, UT Health San Antonio, MD Anderson Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Rodriguez</last_name>
      <phone>210-450-1950</phone>
      <email>rodriguezt1@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Adolfo Enrique Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Argnani</last_name>
      <email>lisa.argnani@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Pier Luigi Zinzani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela DeLorenzo</last_name>
      <email>delorenzo.daniela@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andres Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne</name>
      <address>
        <city>Biała Podlaska</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominika Chwedoruk</last_name>
      <email>dominika.chwedoruk@komed-ck.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Centkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michal Taszner, MD</last_name>
      <email>mtaszner@uck.gda.pl</email>
    </contact>
    <investigator>
      <last_name>Michal Taszner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BioResearch Group Sp. Z. o. o.</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Marek</last_name>
      <email>m.marek@bioresearch.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Jarus-Dziedzic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia McM</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Saweic</last_name>
      <email>anna.sawiec@pratia.com</email>
    </contact>
    <investigator>
      <last_name>Wojciech Jurczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judyta Rudzinska</last_name>
      <email>j.rudzinska@naszlekarz.pl</email>
    </contact>
    <investigator>
      <last_name>Dominik Chraniuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Badalona - Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Casares</last_name>
      <email>mcasares@igtp.cat</email>
    </contact>
    <investigator>
      <last_name>Juan Manuel Sancho Cia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Valer Serra</last_name>
      <email>avaler@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Eva Gonzalez Barca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Armellini</last_name>
    </contact>
    <investigator>
      <last_name>Raul Cordoba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fatima de la Cruz Vicente</last_name>
      <phone>+34 955 01 20 00</phone>
    </contact>
    <investigator>
      <last_name>Fatima de la Cruz Vicente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis de la Cruz Merino</last_name>
      <phone>+34 955 00 80 00</phone>
    </contact>
    <investigator>
      <last_name>Luis de la Cruz Merino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>FL</keyword>
  <keyword>MZL</keyword>
  <keyword>LPL</keyword>
  <keyword>WM</keyword>
  <keyword>MCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

